Literature DB >> 6242485

Tumorigenicity of adenovirus-transformed rat cells and expression of class I major histocompatibility antigen.

G H Mellow, B Föhring, J Dougherty, P H Gallimore, K Raska.   

Abstract

The expression of class I major histocompatibility antigens was studied in six syngeneic adenovirus 12 (Ad12)-transformed LIS rat cell lines of varying tumorigenicity. The concentration of MHC class I product was estimated by indirect immunofluorescence staining of viable cells in suspension with specific antibody and cytofluorographic analysis, and by sensitivity to killing by allogeneic cytolytic T cells (CTLs) elicited by immunization with spleen cells in vivo and in mixed lymphocyte reactions in vitro. None of the rat cell lines examined was devoid of MHC class I antigen. When compared to syngeneic Ad2-transformed cells or fibroblasts, the average intensity of fluorescence of Ad12-transformed lines was lower, suggesting that the concentration of MHC class I antigen is somewhat lower in Ad12-transformed cells. Sensitivity to killing by both in vivo and in vitro induced allogeneic CTLs, however, was not markedly lower with Ad12-transformed cells and correlation was not found between tumorigenic potential in vivo and sensitivity to allogeneic T-cell killing in vitro.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6242485     DOI: 10.1016/0042-6822(84)90313-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

Review 1.  Interactions of viruses with the immune system.

Authors:  C A Mims
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

2.  The level of expression of adenovirus type 2 transforming genes governs sensitivity to nonspecific immune cytolysis and other phenotypic properties of adenovirus 2-simian virus 40-transformed cell hybrids.

Authors:  K Akagi; C T Patch; J L Cook; T Kato; A M Lewis; A S Levine
Journal:  Mol Cell Biol       Date:  1985-08       Impact factor: 4.272

Review 3.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

4.  Tumorigenicity of adenovirus-transformed cells: collagen interaction and cell surface laminin are controlled by the serotype origin of the E1A and E1B genes.

Authors:  F J Bober; D E Birk; T Shenk; K Raska
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

5.  Transcriptional and posttranscriptional regulation of class I major histocompatibility complex genes following transformation with human adenoviruses.

Authors:  J Shemesh; R Rotem-Yehudar; R Ehrlich
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

6.  Tumorigenicity of adenovirus-transformed rodent cells is influenced by at least two regions of adenovirus type 12 early region 1A.

Authors:  T Jelinek; D S Pereira; F L Graham
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

7.  Constructing chimeric type 12/type 5 adenovirus E1A genes and using them to identify an oncogenic determinant of adenovirus type 12.

Authors:  G C Telling; J Williams
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  Expression of histocompatibility antigens H-2K, -D, and -L is reduced in adenovirus-12-transformed mouse cells and is restored by interferon gamma.

Authors:  K B Eager; J Williams; D Breiding; S Pan; B Knowles; E Appella; R P Ricciardi
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

9.  Driving adenovirus type 12-transformed BALB/c mouse cells to express high levels of class I major histocompatibility complex proteins enhances, rather than abrogates, their tumorigenicity.

Authors:  S Soddu; A M Lewis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Expression of the adenovirus E1A oncogene during cell transformation is sufficient to induce susceptibility to lysis by host inflammatory cells.

Authors:  J L Cook; T A Walker; A M Lewis; H E Ruley; F L Graham; S H Pilder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.